• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pheton Holdings Ltd

    8/29/25 4:05:14 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PTHL alert in real time by email
    6-K 1 ea0255273-6k_pheton.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025

     

    Commission File Number: 001-42263

     

    Pheton Holdings Ltd

     

    Room 306, NET Building,

    Hong Jun Ying South Road, Chaoyang District,

    Beijing, China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

     

     

     

    Information Contained in this Form 6-K Report

     

    Entry into a Material Definitive Agreement.

     

    On August 27, 2025, Pheton Holdings Ltd (the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with iTonic Corporation (“Target”) and certain shareholders of the Target (collectively, the “Selling Shareholders”), pursuant to which the Company agreed to acquire, and the Selling Shareholders agreed to sell, 51% of the total outstanding shares of the Target (the “Share Acquisition”). As consideration for the Share Acquisition, the Company agreed to issue to the Selling Shareholders (i) 4,000,000 newly issued Class A ordinary shares of the Company (the “Consideration Shares”), and (ii) warrants to purchase up to 3,000,000 Class A ordinary shares of the Company (the “Warrants”).

     

    The Target develops and provides a home health platform with integrated and automated components, including medication dispensing, supply chain management, virtual care, and patient monitoring. The platform combines hardware and software to deliver medications in the home while also supporting care coordination for patients. The Target is making efforts to deploy the platform across a growing national network of patients, supporting daily care and long-term health management.

     

    Pursuant to the SPA, the Selling Shareholders agreed to enter into lock-up agreements with respect to the Consideration Shares. The Consideration Shares will be subject to release from lock-up upon the achievement of agreed-upon performance milestones set forth in the SPA, which are tied to sales volume and sales revenue generated by the Target. Such milestones will be measured on a quarterly basis beginning January 1, 2026. The Warrants are likewise subject to milestone-based exercisability, as described in the SPA.

     

    The SPA contains customary representations, warranties, and covenants of the parties. The closing of the Share Acquisition is subject to customary closing conditions. 

     

    Unregistered Sales of Equity Securities.

     

    The information contained under “Entry into a Material Definitive Agreement” of this Report on Form 6-K in relation to the Consideration Shares and the Warrants is incorporated herein by reference.

     

    The Consideration Shares and the Warrants, and the Class A ordinary shares issuable upon exercise of the Warrants, are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. Such securities will be issued in reliance on exemptions provided by Section 4(a)(2) and Rule 506(b) of Regulation D thereunder, and pursuant to the exemption provided by Regulation S for offers and sales outside the U.S. 

     

    Forward Looking Statements

     

    Certain statements in this Report are not historical facts, including, without limitation, statements relating to the Share Acquisition, including the ability to complete, and the timing of completion of, the transactions contemplated by the SPA, including the parties’ ability to satisfy the conditions set forth in the SPA and the possibility of any termination of the SPA and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” “continues,” or similar expressions. Such statements are based upon the current beliefs and expectations of management of the Company. These statements are subject to risks, uncertainties, changes in circumstances, assumptions and other important factors, many of which are outside management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Actual results may differ materially from current expectations because of numerous risks and uncertainties including, among others: (1) the risk that the proposed transaction may not be completed in a timely manner or at all; (2) the risk of legal proceedings that may be instituted against the Company and/or the Selling Shareholders related to the SPA, which may result in significant costs of defense, indemnification and liability; (3) the possibility that any or all of the various conditions to the consummation of the Share Acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Share Acquisition; (4) the occurrence of any event, change or other circumstance that could give rise to the termination of the SPA; (5) the effects of disruption from the transactions on Selling Shareholders’ or the Company’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees and business partners; and (6) conditions beyond Selling Shareholders’ and the Company’s control such as timing of holidays, weather, natural disasters, acts of war or terrorism. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s most recent Annual Report on Form 20-F for the year ended December 31, 2024. The Company’s shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Pheton Holdings Ltd
         
    Date: August 29, 2025 By: /s/ Jianfei Zhang
      Name:  Jianfei Zhang
      Title:

    Chief Executive Officer and

    Chairman of the Board of Directors

     

    2

     

    Get the next $PTHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change

    BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the Company's Class A ordinary shares will cease trading under the current ticker symbol "PTHL" and will begin tradi

    1/13/26 8:30:00 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation

    Beijing, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) ("Pheton" or the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the successful completion of its acquisition of 51% of the total outstanding shares of iTonic Corporation (the "Target"), a U.S.-based integrated home health AI company that combines AI, medical device automation, and easier access to clinical expertise to support continuity of care in the home (the "Share Acquisition"). This strategic acquisition aligns with the Company's commitment to enhancing its portfolio in the healthcare tech

    12/5/25 4:05:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) (the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced, on October 20, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based on the closing bid price of the Class A ordinary shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Th

    10/23/25 4:15:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PTHL
    SEC Filings

    View All

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    1/13/26 4:00:30 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/22/25 7:43:23 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/16/25 12:58:56 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care